Abstract: A medical table wherein a top board on which a patient is placed is supported by a base having an internal instrument so as to be movable parallel to the board surface, the medical table includes a detecting device that detects the possibility that a hand or fingers, which grip the top board, come in contact with the internal instrument during the movement of the top board or internal instrument, and a preventing device that prevents the movement of the top board or the internal instrument on the basis of a detection signal of the detecting device

Abstract: A medical table in which a top plate for a patient to lie on is supported by a pedestal base in a manner to be able to move parallel to a plate surface, includes a detecting device for detecting that fingers holding the top plate are about to collide against the pedestal base when moving the top plate, and a stopping device for stopping movement of the top plate according to a detection signal from the detecting device.

Abstract: The present invention discloses four groups of SCN5A variants that represent the most common SCN5A variants in humans. A specific mutation in one of the variants has been shown to display a different phenotype in relation to a human heart disease than other variants and known human sodium channel ? subunits with corresponding mutations. The present invention provides new tools to study mutations and to design or identify new diagnostic and treatment strategies or agents for sodium channel related diseases or conditions.

Abstract: The present invention relates to isolated sulfonylurea receptor polynucleotides and polypeptides, as well as vectors and cells lines containing the polynucleotides and polypeptides. The present invention also relates to methods of using cell lines containing the polynucleotides and polypeptides to identify agents that are useful in ischemic preconditioning.

Abstract: This invention provides novel dihydropyridine derivatives of the formula I having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.

Abstract: A radiographic system(100) is provided wherein a single X-ray detector can be handled freely using a cable and which can prevent an operator or a patient from being troubled by the cable. The radiographic system(100) comprises a radiographic panel(5) configured to radiograph in two dimensions a radiation exposed to a subject and output radiation image data, a cable(6) for the supply of electric power to the radiographic panel and transfer of the radiation image data, a conveyance unit(8) for conveying the cable in a predetermined direction, a cable length adjusting unit(7) provided in the conveyance unit to adjust the length of the cable, and a movement control unit(72) configured to move the conveyance unit in accordance with a tilting direction of the cable from the cable length adjusting unit to the radiographic panel.

Abstract: The present invention is directed to methods of identifying women at increased risk of having ovarian cancer. Identification is based upon the extent to which biological samples derived from the women exhibit elevated levels of eosinophil-derived neurotoxin (EDN).

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4a, R4b, R4c, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, R9 and R10 are described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of using and preparing the compounds of the invention are also disclosed.

Abstract: The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.

Abstract: Pharmaceutical compositions containing taxanes having about 5 to about 75% phospholipid, about 0.01 to about 50% of a surfactant of an HLB value greater than 10, about 0.01 to about 50% alcohol and about 0.01 to about 40% taxane(s) or a derivative thereof.

Abstract: The present invention is directed to a method for determining whether a woman has, or is likely to develop, ovarian cancer based upon assays of the alpha subunit of haptoglobin.

Abstract: The present invention relates to compounds which are CCR-5 receptor antagonists of the general formula I: wherein R1, R2, R3, R4, Ra, Rb, Rc, Rd, X, m and n are as defined herein. The invention further comprises pharmaeceutical compositions comprising such compounds, as well as the use of such compounds to treat CCR-5 mediated disorders.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: The present invention relates to a series of compounds which are CCR-5 receptor antagonists of the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: The present invention is directed to diagnostic methods based upon the expression of the protein osteopontin. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer.